Microorganisms (Apr 2022)

Fighting Enteroviral Infections to Prevent Type 1 Diabetes

  • Magloire Pandoua Nekoua,
  • Ambroise Mercier,
  • Abdulaziz Alhazmi,
  • Famara Sane,
  • Enagnon Kazali Alidjinou,
  • Didier Hober

DOI
https://doi.org/10.3390/microorganisms10040768
Journal volume & issue
Vol. 10, no. 4
p. 768

Abstract

Read online

Enteroviruses (EVs), especially coxsackieviruses B (CVB), are believed to trigger or accelerate islet autoimmunity in genetically susceptible individuals that results in type 1 diabetes (T1D). Therefore, strategies are needed to fight against EV infections. There are no approved antiviral drugs currently available, but various antiviral drugs targeting viral or host cell proteins and vaccines have recently shown potential to combat CVB infections and may be used as new therapeutic strategies to prevent or reduce the risk of T1D and/or preserve β-cell function among patients with islet autoantibodies or T1D.

Keywords